SAN DIEGO, March 7, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, will
present preclinical data from studies involving in vivo
intratumoral IL-12 treatment in mouse cancer models. The data
will be presented in a poster at an upcoming Keystone Symposia
conference. In addition, Punit
Dhillon, OncoSec President and CEO, will present a corporate
overview at two investment conferences this month, including:
Maxim Group's Inaugural Healthcare Investor & Partnering
Conference and the 2017 BIO Asia International
Conference.
Keystone Symposia Conference: Cancer Immunology and
Immunotherapy: Taking a Place in Mainstream Oncology
OncoSec will present a poster at the Cancer Immunology and
Immunotherapy: Taking a Place in Mainstream Oncology conference to
be held on March 19-23, 2017, in
Whistler, British Columbia,
Canada. Details of the presentation are as follows:
Abstract
Title: Intratumoral electroporation-mediated IL-12 gene therapy
can enhance tumor Immunogenicity (Poster #2074)
|
|
|
|
Date and Time:
Tuesday, March 21, 2017 at 11:00 AM PST
|
|
|
|
Location:
Fairmont Chateau Whistler
|
|
Further details on this Keystone Symposia poster presentation
will be provided in upcoming Company communications. For more
information about this conference, please visit:
http://keystonesymposia.org.
Maxim Group's Inaugural Healthcare Investor & Partnering
Conference
Mr. Dhillon will present a corporate overview at Maxim Group's
Biotech Investor & Partnering
Conference on March 7, 2017 at
11:20 AM China Standard Time at The
Park Hyatt Shanghai in Shanghai,
China. In addition, he will participate in a panel
discussion entitled: "Innovations in Oncology – From Chemo to
Immunotherapy" on the same day at 10:00
AM local time. For more information about this conference,
please visit: http://www.maximgrp.com.
BIO Asia International Conference
Mr. Dhillon will present a corporate overview at the BIO Asia
International Conference on March 14,
2017 at 11:15 AM Japanese
Standard Time at the Grand Hyatt Tokyo in Tokyo, Japan. For more information about this
conference, please visit:
https://www.bio.org/events/bio-asia-internationalconference.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse®
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile and evidence of anti-tumor activity in the treatment
of various solid tumors as well as a systemic immune response.
OncoSec's lead program, ImmunoPulse® IL-12, is currently
in clinical development for metastatic melanoma and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse® platform. For more information, please visit
www.oncosec.com.
CONTACTS:
Investor Relations:
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media:
Laura Radocaj
DGI Comm
212-825-3210
media@oncosec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-march-300419332.html
SOURCE OncoSec Medical Incorporated